NASDAQ:ZIOP - ZIOPHARM Oncology Stock Price, Forecast & News

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.34. View ZIOPHARM Oncology's Earnings History.

ZIOPHARM Oncology is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for ZIOPHARM Oncology.

ZIOPHARM Oncology will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 brokers have issued 12-month price targets for ZIOPHARM Oncology's stock. Their forecasts range from $6.50 to $7.50. On average, they anticipate ZIOPHARM Oncology's share price to reach $6.88 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZIOPHARM Oncology.

News articles about ZIOP stock have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ZIOPHARM Oncology earned a news impact score of 2.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for ZIOPHARM Oncology.

Some companies that are related to ZIOPHARM Oncology include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Intrexon (XON), Celgene (CELG), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Immunomedics (IMMU), Opko Health (OPK), Arena Pharmaceuticals (ARNA), Inovio Pharmaceuticals (INO) and Sangamo Therapeutics (SGMO).

ZIOPHARM Oncology's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (3.28%), Geode Capital Management LLC (1.23%), Charles Schwab Investment Management Inc. (0.55%), UBS Group AG (0.38%), Bank of New York Mellon Corp (0.38%) and California Public Employees Retirement System (0.20%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield. View Institutional Ownership Trends for ZIOPHARM Oncology.

ZIOP stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, Rafferty Asset Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Creative Planning and New York State Common Retirement Fund. Company insiders that have sold ZIOPHARM Oncology company stock in the last year include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield. View Insider Buying and Selling for ZIOPHARM Oncology.

ZIOP stock was bought by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Geode Capital Management LLC, First Trust Advisors LP, California Public Employees Retirement System, UBS Asset Management Americas Inc., Bank of New York Mellon Corp, Vident Investment Advisory LLC and Virtus ETF Advisers LLC. View Insider Buying and Selling for ZIOPHARM Oncology.

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZIOP stock can currently be purchased for approximately $2.99.

ZIOPHARM Oncology has a market capitalization of $541.28 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-53,120,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe.View Additional Information About ZIOPHARM Oncology.

The official website for ZIOPHARM Oncology is http://www.ziopharm.com/.

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]